Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.
BACKGROUND: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI) nephrotoxicity....
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Journal article |
语言: | English |
出版: |
2013
|